Raw cannabis compound shows unique anti-cancer properties

This groundbreaking study explores how cannabidiolic acid (CBDA)—the raw, acidic form of CBD found in fresh cannabis plants—affects colorectal cancer (CRC) cells differently than its better-known counterpart. Researchers compared the effects of CBD, CBDA, and a CBDA-rich Cannabis sativa extract on cancer cell viability and gene expression in CRC cell lines. While CBD has been extensively studied for its anticancer properties, CBDA has received far less attention despite emerging evidence suggesting it may have unique therapeutic mechanisms, particularly through cyclooxygenase signaling pathways.

The findings reveal that CBDA and CBD affect colorectal cancer cells through distinct molecular pathways, with CBDA demonstrating notable effects on mRNA expression that differ from CBD's mechanisms. This research represents the first investigation into how CBDA influences RNA expression and signaling in colorectal cancer cells, filling a critical gap in our understanding of raw versus decarboxylated cannabinoids. The study suggests that consuming raw cannabis or CBDA-rich extracts may offer different anticancer benefits compared to heated cannabis products that convert CBDA to CBD, potentially opening new avenues for cannabinoid-based cancer therapies and emphasizing the importance of preservation methods in medical cannabis products.